Myriad Genetics reports positive 2023 results, eyes growth By Investing.com
© Reuters. Myriad Genetics (NASDAQ:) has reported a positive financial outlook in their fourth quarter and full year 2023 earnings call, with an 11% increase in total revenue compared to the previous year. The company achieved positive adjusted earnings per share (EPS) and operating cash flow in Q4 and raised their revenue guidance for 2024. … Read more